Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VCSH | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Fixed Income |
52-Week High | $812.27 | $80.20 |
52-Week Low | $545.46 | $78.45 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VCSH trades at $78.64, down 0.1% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent dividend payout, with recent distributions of $0.29-$0.30 per share. News highlights institutional interest, such as Allspring Global Investments' 1.47 million share purchase in July 2026, while comparisons with peers like ISTB focus on yield and diversification.
The outlook remains cautious due to the bearish technical setup and potential interest rate volatility. Opportunities include the ETF's high yield and low expense ratio, but risks involve Fed policy uncertainty and competitive pressure from other short-term bond funds. Investor sentiment is mixed, balancing income appeal against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
